Afficher la notice abrégée

dc.contributor.authorBellocchi, Chiara
dc.contributor.authorFernández Ochoa, Álvaro 
dc.contributor.authorMontanelli, Gaia
dc.contributor.authorVigone, Barbara
dc.contributor.authorSantaniello, Alessandro
dc.contributor.authorMilani, Christian
dc.contributor.authorQuirantes-Piné, Rosa
dc.contributor.authorBorras Linares, María Isabel 
dc.contributor.authorVentura, Marco
dc.contributor.authorSegura-Carrettero, Antonio
dc.contributor.authorAlarcón Riquelme, Marta Eugenia 
dc.contributor.authorBeretta, Lorenzo
dc.date.accessioned2019-02-19T13:19:15Z
dc.date.available2019-02-19T13:19:15Z
dc.date.issued2018
dc.identifier.citationNombre(s), p.ej. Manuel Bellocchi, Chiara; Fernández-Ochoa, Álvaro; Montanelli, Gaia; Vigone, Barbara; Santaniello, Alessandro; Milani, Christian; Quirantes-Piné, Rosa; Borrás-Linares, Isabel; Ventura, Marco; Segura-Carrettero, Antonio; Alarcón Riquelme, Marta Eugenia; Beretta, Lorenzo. Microbial and metabolic multi-omic correlations in systemic sclerosis patients. Ann. N.Y. Acad. Sci. 1421 (2018) 97–109. [http://hdl.handle.net/10481/54802]es_ES
dc.identifier.issn0077-8923
dc.identifier.urihttp://hdl.handle.net/10481/54802
dc.description.abstractIntestinal microbiota has been associated with systemic autoimmune diseases, yet the functional consequences of these associations are elusive.We characterized the fecal microbiota (16S rRNA gene amplification and sequencing) and the plasma metabolome (high-performance liquid chromatography coupled to mass spectrometry) in 59 patients with systemic sclerosis (SSc) and 28 healthy controls (HCs).Microbial and metabolic data were cross-correlated to find meaningful associations after extensive data mining analysis and internal validation. Our data show that a reduced model of nine bacteria is capable of differentiating HCs from SSc patients. SSc gut microbiota is characterized by a reduction in protective butyrate-producing bacteria and by an increase in proinflammatory noxious genera, especially Desulfovibrio. From the metabolic point of view, a multivariate model with 17 metabolite intermediates well distinguished cases from controls. The most interesting peaks we found were identified as glycerophospholipid metabolites and benzene derivatives. The microbial and metabolic data showed significant interactions between Desulfovibrio and alpha-N-phenylacetyl-l-glutamine and 2,4-dinitrobenzenesulfonic acid. Our data suggest that in SSc, intestinal microbiota is characterized by proinflammatory alterations subtly entwined with the metabolic state. Desulfovibrio is a relevant actor in gut dysbiosis that may promote intestinal damage and influence amino acid metabolism.es_ES
dc.description.sponsorshipThis work was supported by EU/EFPIA/Innovative Medicines Initiative Joint Undertaking PRECISESADS grant No. 115565.es_ES
dc.language.isoenges_ES
dc.publisherWiley Periodicals Inc. on behalf of The New York Academy of Scienceses_ES
dc.rightsAtribución-NoComercial 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.subjectSystemic sclerosises_ES
dc.subjectMicrobiotaes_ES
dc.subjectMetabolomees_ES
dc.subjectGastrointestinales_ES
dc.titleMicrobial and metabolic multi-omic correlations in systemic sclerosis patientses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución-NoComercial 3.0 España
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución-NoComercial 3.0 España